Predict your next investment

MedAlliance company logo
HEALTHCARE | Medical Devices & Equipment / Surgical Devices

See what CB Insights has to offer


Private Equity | Alive

Total Raised


About MedAlliance

MedAlliance is a privately-owned medical technology company that focuses on developing medical products for the treatment of coronary and peripheral artery disease. The company's DCB technology is a next-generation approach for patients with peripheral artery disease (PAD), coronary artery disease (CAD), and arteriovenous fistulas (AVF). With unique micro-reservoirs, the technology efficiently delivers sirolimus to the target lesion, where it provides controlled and sustained release. MedAlliance's technology will further enable surgeons' desire to move away from metal scaffolds and durable polymers that remain within the patient in PAD by providing a safer and more effective alternative to paclitaxel-coated balloons.

MedAlliance Headquarter Location

Rue de Rive 5

Nyon, 1260,


+ 41 22 363 78 90

Latest MedAlliance News

MedAlliance launches two new balloons for vessel preparation

Jul 21, 2021

MedAlliance launches two new balloons for vessel preparation 21 July 2021 × Origin SC is a semi-compliant (SC) PTCA balloon with a very low crossing profile, making it an excellent choice for challenging lesions. Origin SC offers one of the broadest portfolio of sizes available for an SC balloon, including 1.00 mm, 1.25 mm, 1.50 mm and 1.75 mm balloon diameters to treat very small vessels and complex cases. Origin NC is a non-compliant (NC) PTCA balloon, combining high pressure tolerance and controlled compliance with an optimal crossing profile for the most challenging cases. Origin NC’s minimal balloon longitudinal growth ensures focussed dilatation force on the target lesion, minimising the risk of damaging healthy tissue. Origin NC also offers low crossing profiles among all categories of PTCA balloon catheter currently available. It is particularly appropriate when facing tight stenoses in calcified, fibrotic lesions. Drug-Eluting Balloons (DEBs) such as Selution SLR are designed to effectively deliver drug to the lesion site rather than dilate the vessel. This is why PTCA balloons designed for vessel preparation such as Origin SC and Origin NC are particularly appropriate in a pre-dilation role. These balloons, however, do not have to be used exclusively in conjunction with Selution SLR: they can be used on their own, for example to pre-dilate a vessel prior to stent implantation or to post-dilate a coronary stent to achieve accurate and controlled stent expansion. Jeffrey B. Jump, chairman and CEO of MedAlliance, said "We are excited to be broadening our balloon portfolio with the ORIGIN range which complements our flagship DEB Selution SLR. This is just the start of our product expansion program to vertically integrate high quality products for the benefit of patients around the world.” MedAlliance’s DEB technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhere to the vessel lumen when delivered via an angioplasty balloon. Selution SLR was awarded CE mark approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020. It is now available in Europe and all other countries where the CE mark is recognised.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MedAlliance

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MedAlliance is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

MedAlliance Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MedAlliance Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.